Global Transdermal Drug Delivery Systems Market Insights, Forecast to 2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Transdermal Drug Delivery Systems Revenue
• 1.4 Market by Type
  • 1.4.1 Global Transdermal Drug Delivery Systems Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Fentanyl
  • 1.4.3 Nitroglycerin
  • 1.4.4 Estradiol
  • 1.4.5 Nicotine
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Transdermal Drug Delivery Systems Market Share by Application: 2020 VS 2026
  • 1.5.2 OTC
  • 1.5.3 Rx
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Transdermal Drug Delivery Systems Market Perspective (2015-2026)
• 2.2 Global Transdermal Drug Delivery Systems Growth Trends by Regions
  • 2.2.1 Transdermal Drug Delivery Systems Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Transdermal Drug Delivery Systems Historic Market Share by Regions (2015-2020)
  • 2.2.3 Transdermal Drug Delivery Systems Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Transdermal Drug Delivery Systems Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Transdermal Drug Delivery Systems Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Transdermal Drug Delivery Systems Players by Market Size
  • 3.1.1 Global Top Transdermal Drug Delivery Systems Players by Revenue (2015-2020)
  • 3.1.2 Global Transdermal Drug Delivery Systems Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Transdermal Drug Delivery Systems Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Transdermal Drug Delivery Systems Market Concentration Ratio
  • 3.2.1 Global Transdermal Drug Delivery Systems Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Transdermal Drug Delivery Systems Revenue in 2019
• 3.3 Transdermal Drug Delivery Systems Key Players Head office and Area Served
• 3.4 Key Players Transdermal Drug Delivery Systems Product Solution and Service
• 3.5 Date of Enter into Transdermal Drug Delivery Systems Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Transdermal Drug Delivery Systems Historic Market Size by Type (2015-2020)
• 4.2 Global Transdermal Drug Delivery Systems Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
• 5.2 Global Transdermal Drug Delivery Systems Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Transdermal Drug Delivery Systems Market Size (2015-2020)
• 6.2 Transdermal Drug Delivery Systems Key Players in North America (2019-2020)
• 6.3 North America Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
• 6.4 North America Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Transdermal Drug Delivery Systems Market Size (2015-2020)
• 7.2 Transdermal Drug Delivery Systems Key Players in Europe (2019-2020)
• 7.3 Europe Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
• 7.4 Europe Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

8 China

• 8.1 China Transdermal Drug Delivery Systems Market Size (2015-2020)
• 8.2 Transdermal Drug Delivery Systems Key Players in China (2019-2020)
• 8.3 China Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
• 8.4 China Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Transdermal Drug Delivery Systems Market Size (2015-2020)
• 9.2 Transdermal Drug Delivery Systems Key Players in Japan (2019-2020)
• 9.3 Japan Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
• 9.4 Japan Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Transdermal Drug Delivery Systems Market Size (2015-2020)
• 10.2 Transdermal Drug Delivery Systems Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
• 10.4 Southeast Asia Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

11 India

• 11.1 India Transdermal Drug Delivery Systems Market Size (2015-2020)
• 11.2 Transdermal Drug Delivery Systems Key Players in India (2019-2020)
• 11.3 India Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
• 11.4 India Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Transdermal Drug Delivery Systems Market Size (2015-2020)
• 12.2 Transdermal Drug Delivery Systems Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
• 12.4 Central & South America Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Hisamitsu
  • 13.1.1 Hisamitsu Company Details
  • 13.1.2 Hisamitsu Business Overview
  • 13.1.3 Hisamitsu Transdermal Drug Delivery Systems Introduction
  • 13.1.4 Hisamitsu Revenue in Transdermal Drug Delivery Systems Business (2015-2020))
  • 13.1.5 Hisamitsu Recent Development
• 13.2 Mylan
  • 13.2.1 Mylan Company Details
  • 13.2.2 Mylan Business Overview
  • 13.2.3 Mylan Transdermal Drug Delivery Systems Introduction
  • 13.2.4 Mylan Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.2.5 Mylan Recent Development
• 13.3 GSK
  • 13.3.1 GSK Company Details
  • 13.3.2 GSK Business Overview
  • 13.3.3 GSK Transdermal Drug Delivery Systems Introduction
  • 13.3.4 GSK Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.3.5 GSK Recent Development
• 13.4 Novartis
  • 13.4.1 Novartis Company Details
  • 13.4.2 Novartis Business Overview
  • 13.4.3 Novartis Transdermal Drug Delivery Systems Introduction
  • 13.4.4 Novartis Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.4.5 Novartis Recent Development
• 13.5 Teve(Actavis)
  • 13.5.1 Teve(Actavis) Company Details
  • 13.5.2 Teve(Actavis) Business Overview
  • 13.5.3 Teve(Actavis) Transdermal Drug Delivery Systems Introduction
  • 13.5.4 Teve(Actavis) Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.5.5 Teve(Actavis) Recent Development
• 13.6 Johnson & Johnson
  • 13.6.1 Johnson & Johnson Company Details
  • 13.6.2 Johnson & Johnson Business Overview
  • 13.6.3 Johnson & Johnson Transdermal Drug Delivery Systems Introduction
  • 13.6.4 Johnson & Johnson Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.6.5 Johnson & Johnson Recent Development
• 13.7 UCB
  • 13.7.1 UCB Company Details
  • 13.7.2 UCB Business Overview
  • 13.7.3 UCB Transdermal Drug Delivery Systems Introduction
  • 13.7.4 UCB Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.7.5 UCB Recent Development
• 13.8 Teikoku Seiyaku
  • 13.8.1 Teikoku Seiyaku Company Details
  • 13.8.2 Teikoku Seiyaku Business Overview
  • 13.8.3 Teikoku Seiyaku Transdermal Drug Delivery Systems Introduction
  • 13.8.4 Teikoku Seiyaku Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.8.5 Teikoku Seiyaku Recent Development
• 13.9 Bayer
  • 13.9.1 Bayer Company Details
  • 13.9.2 Bayer Business Overview
  • 13.9.3 Bayer Transdermal Drug Delivery Systems Introduction
  • 13.9.4 Bayer Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.9.5 Bayer Recent Development
• 13.10 Lingrui
  • 13.10.1 Lingrui Company Details
  • 13.10.2 Lingrui Business Overview
  • 13.10.3 Lingrui Transdermal Drug Delivery Systems Introduction
  • 13.10.4 Lingrui Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 13.10.5 Lingrui Recent Development
• 13.11 Sanofi
  • 10.11.1 Sanofi Company Details
  • 10.11.2 Sanofi Business Overview
  • 10.11.3 Sanofi Transdermal Drug Delivery Systems Introduction
  • 10.11.4 Sanofi Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.11.5 Sanofi Recent Development
• 13.12 Qizheng
  • 10.12.1 Qizheng Company Details
  • 10.12.2 Qizheng Business Overview
  • 10.12.3 Qizheng Transdermal Drug Delivery Systems Introduction
  • 10.12.4 Qizheng Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.12.5 Qizheng Recent Development
• 13.13 Endo
  • 10.13.1 Endo Company Details
  • 10.13.2 Endo Business Overview
  • 10.13.3 Endo Transdermal Drug Delivery Systems Introduction
  • 10.13.4 Endo Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.13.5 Endo Recent Development
• 13.14 Huarun 999
  • 10.14.1 Huarun 999 Company Details
  • 10.14.2 Huarun 999 Business Overview
  • 10.14.3 Huarun 999 Transdermal Drug Delivery Systems Introduction
  • 10.14.4 Huarun 999 Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.14.5 Huarun 999 Recent Development
• 13.15 Haw Par
  • 10.15.1 Haw Par Company Details
  • 10.15.2 Haw Par Business Overview
  • 10.15.3 Haw Par Transdermal Drug Delivery Systems Introduction
  • 10.15.4 Haw Par Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.15.5 Haw Par Recent Development
• 13.16 Nichiban
  • 10.16.1 Nichiban Company Details
  • 10.16.2 Nichiban Business Overview
  • 10.16.3 Nichiban Transdermal Drug Delivery Systems Introduction
  • 10.16.4 Nichiban Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.16.5 Nichiban Recent Development
• 13.17 Mentholatum Company
  • 10.17.1 Mentholatum Company Company Details
  • 10.17.2 Mentholatum Company Business Overview
  • 10.17.3 Mentholatum Company Transdermal Drug Delivery Systems Introduction
  • 10.17.4 Mentholatum Company Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.17.5 Mentholatum Company Recent Development
• 13.18 Laboratoires Genevrier
  • 10.18.1 Laboratoires Genevrier Company Details
  • 10.18.2 Laboratoires Genevrier Business Overview
  • 10.18.3 Laboratoires Genevrier Transdermal Drug Delivery Systems Introduction
  • 10.18.4 Laboratoires Genevrier Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
  • 10.18.5 Laboratoires Genevrier Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer